DRG Market Assessment reports

The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral…

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibitors have transformed the management of…

Immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, Merck & Co.’s Keytruda, and Roche’s Tecentriq, are revolutionizing the therapeutic strategies for several cancers. This…

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva),…

Market Outlook Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routinely used throughout the…

A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug…

Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disorder that leads to progressive muscle wasting and weakness. The typical survival time is three to five years from onset. The…

Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both…

As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…

Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR mutations lead…

Recent European approval of three anti-CGRP-targeted MAbs—Aimovig (Novartis), Ajovy (Teva) and Emgality (Eli Lilly)—together with the expected market penetration of the fourth anti-CGRP-…

Myelofibrosis (MF) is a hematological malignancy characterized by the disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, weakness, fatigue, and…